Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598136 | 0.88 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL7820476 | 0.88 | L3MBTL1 (0.54) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL6171584 | 0.87 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1L3MBTL1HTTOPRD1 | |
| SCHEMBL6167989 | 0.86 | LMNA (0.63) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL6171225 | 0.86 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL6171747 | 0.85 | LMNA (0.52) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL6170025 | 0.84 | LMNA (0.52) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 | |
| SCHEMBL6170440 | 0.83 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1L3MBTL1OPRK1LMNA | |
| SCHEMBL6173909 | 0.83 | OPRD1 (0.64) | L3MBTL1OPRD1OPRK1OPRM1 | |
| SCHEMBL6168151 | 0.82 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1L3MBTL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112255-B1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040138220-A1 | 4,4-Biarylpiperidine derivatives | PFIZER, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6720336-B2 | USED AS LIGANDS FOR OPIOID RECEPTORS, FOR THERAPY OF NEUROLOGICAL AND GASTROINTESTINAL DISORDERS | PFIZER, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1112255-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014066-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138220-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | SIGMAR1 365/4885ALDH1A1 178/4885L3MBTL1 2507/4885 |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | SIGMAR1 365/4885ALDH1A1 178/4885L3MBTL1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.